At EVO NXT 2026, the Global Institute for Novel Nicotine opened its programme with a panel session examining the latest scientific evidence, regulatory frameworks, and public health considerations surrounding tobacco harm reduction. The session was moderated by Philipp Markl and featured contributions from Dr Sydney Hiller, Sairah Salim-Sartoni, and John Dunne, bringing together perspectives from…
EVO NXT 2026 officially opened on April 17, 2026, at Forum Karlín in Prague, bringing together stakeholders from across the next-generation products (NGP) sector, including manufacturers, regulators, researchers, and public health representatives. Positioned as a business-focused event, EVO NXT serves as a platform for examining how innovation, regulation, and market developments are shaping the future…
Over the last decade, smoking has fallen across most high-income countries, but not at the same pace. In some jurisdictions, the decline has been steep; in others, more gradual and persistent. This variation is not solely explained by cultural or economic factors. It reflects differences in regulatory design and how policymakers approach nicotine use. This…
The nicotine pouch category is evolving rapidly across global markets, driven by regulatory shifts, growing consumer adoption, and strategic investment from major industry players. At GINN, we are building an AI-powered monitoring system designed to track global nicotine and oral product developments with greater speed, accuracy, and relevance. The concept is simple: AI scans hundreds…
Building on our initial look at the Commission’s TPD evaluation, the Tobacco Advertising Directive (TAD) is now being reframed to treat all nicotine products—traditional or novel—as part of a single regulatory category. The emphasis is shifting from differentiated risk communication to a comprehensive, product‑agnostic ban on advertising, promotion, and sponsorship. 📑 Key Shifts in Policy…
The Commission’s evaluation of the Tobacco Products Directive (TPD) 🎯 substantially overstates its public‑health success and fails to provide a credible evidence base for risk‑proportionate regulation of low‑risk nicotine products. 🔍 Framing & Methodology • Smoking prevalence reduction is treated as the main success metric, yet the evaluation does not convincingly isolate the TPD’s impact…
Comparative public health outcomes across countries can provide valuable insight into how regulatory frameworks shape behaviour, risk exposure, and long-term disease burden. A recent comparative analysis of Brazil and New Zealand highlights how differing policy approaches toward nicotine products are associated with divergent trends in smoking prevalence. Both countries have implemented strong tobacco control measures…
Ireland’s upcoming Presidency of the Council of the European Union presents a strategic opportunity to shape Europe’s public health agenda at a time of growing pressure on health systems and widening inequalities in outcomes. Recent discussions highlight a clear direction: stronger coordination, a renewed focus on prevention, and the need to address high-burden diseases through…
New U.S. evidence highlights patterns relevant to harm reduction policy As nicotine pouches (ONPs) continue to expand in the United States, understanding how adult smokers engage with these products is becoming increasingly important for evidence-based regulation. A recent peer-reviewed study using nationally representative data from the Population Assessment of Tobacco and Health (PATH) Study provides…
A productive and timely discussion in Vilnius with a European Parliament delegation led by Auke Zijlstra, MEP & Sebastian Kruis, MEP, Wilson George Group, NOIS Nicotine Pouches, Johan Nissinen, Glick®, Chubby Gorilla®, Inc., Adam Gambrill,Tautvydas Kviliunas and Andrius Miskelevicius on the evolving regulatory landscape for nicotine pouches across the Baltics and Europe. At the recent…